Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IPR-803 是一种有效的 uPAR·uPA 蛋白-蛋白相互作用抑制剂,具有抗肿瘤活性。 IPR-803 直接与 uPAR 结合,Ki 为 0.2 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 849 | 现货 | ||
5 mg | ¥ 1,980 | 现货 | ||
10 mg | ¥ 3,230 | 现货 | ||
25 mg | ¥ 5,290 | 现货 | ||
50 mg | ¥ 7,490 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,220 | 现货 |
产品描述 | IPR-803 is an effective inhibitor of the uPAR·uPA protein-protein interaction (PPI) with anti-tumor activity. IPR-803 binds directly to uPAR with a Ki of 0.2 μM. |
靶点活性 | PPI:ki: 0.2 μM |
体外活性 | IPR-803 (0-200 μM; 3 days) blocks the invasion of MDA-MB-231 cells, and most of the inhibition of cell invasion is unlikely due to the cytotoxicity of the compound. IPR-803 (50 μM; 30 minutes) shows inhibition of MAPK phosphorylation. IPR-803 blocks invasion of breast cancer cells line MDA-MB-231, and inhibits matrix metalloproteinase breakdown of the extracellular matrix. IPR-803 impairs MDA-MB-231 cell adhesion and migration. IPR-803 induces a concentration-dependent impairment of cell adhesion with an IC50 of 30 μM. IPR-803 inhibits MDA-MB-231 cells growth with an IC50 of 58 μM[1]. |
体内活性 | In NSG mice with MDA-MB-231 cells xenograft, IPR-803 (200 mg/kg; i.g.; three times a week; for 5 weeks) impairs breast cancer metastasis with a t1/2 of 5 hours. IPR-803 has a low oral bioavailability at 4 percent, and remains high concentration even after 10 hours in tumor tissue[1]. |
分子量 | 453.49 |
分子式 | C27H23N3O4 |
CAS No. | 892243-35-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 7 mg/mL (15.44 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2051 mL | 11.0256 mL | 22.0512 mL | 55.128 mL |
5 mM | 0.441 mL | 2.2051 mL | 4.4102 mL | 11.0256 mL | |
10 mM | 0.2205 mL | 1.1026 mL | 2.2051 mL | 5.5128 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
IPR-803 892243-35-5 Cell Cycle/Checkpoint Metabolism Serine/threonin kinase inhibit Inhibitor Threonine proteases Serine proteases Ser/Thr Protease IPR803 Serine endopeptidases IPR 803 inhibitor